CN101626784B - 利用包含抗体的组合物治疗和/或预防非传染性医学病症 - Google Patents

利用包含抗体的组合物治疗和/或预防非传染性医学病症 Download PDF

Info

Publication number
CN101626784B
CN101626784B CN200780039676XA CN200780039676A CN101626784B CN 101626784 B CN101626784 B CN 101626784B CN 200780039676X A CN200780039676X A CN 200780039676XA CN 200780039676 A CN200780039676 A CN 200780039676A CN 101626784 B CN101626784 B CN 101626784B
Authority
CN
China
Prior art keywords
antibody
ephb4
cancer
dairy
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200780039676XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101626784A (zh
Inventor
安东尼·威廉姆·斯卡梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Comco As Trustee Of A Trust Co Acn135493391 Ltd By Share Ltd
Original Assignee
Comco As Trustee Of A Trust Co Acn135493391 Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904752A external-priority patent/AU2006904752A0/en
Application filed by Comco As Trustee Of A Trust Co Acn135493391 Ltd By Share Ltd filed Critical Comco As Trustee Of A Trust Co Acn135493391 Ltd By Share Ltd
Publication of CN101626784A publication Critical patent/CN101626784A/zh
Application granted granted Critical
Publication of CN101626784B publication Critical patent/CN101626784B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200780039676XA 2006-08-31 2007-08-31 利用包含抗体的组合物治疗和/或预防非传染性医学病症 Expired - Fee Related CN101626784B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904752 2006-08-31
AU2006904752A AU2006904752A0 (en) 2006-08-31 Uses for Antibodies
PCT/AU2007/001282 WO2008025099A1 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions

Publications (2)

Publication Number Publication Date
CN101626784A CN101626784A (zh) 2010-01-13
CN101626784B true CN101626784B (zh) 2013-07-17

Family

ID=39135433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780039676XA Expired - Fee Related CN101626784B (zh) 2006-08-31 2007-08-31 利用包含抗体的组合物治疗和/或预防非传染性医学病症

Country Status (8)

Country Link
US (2) US20100297140A1 (enExample)
EP (1) EP2061510B1 (enExample)
JP (1) JP2010501596A (enExample)
CN (1) CN101626784B (enExample)
AU (1) AU2007291891B2 (enExample)
DK (1) DK2061510T3 (enExample)
NZ (1) NZ575918A (enExample)
WO (1) WO2008025099A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
ES2684696T3 (es) 2009-04-27 2018-10-04 Immuron Limited Preparación de inmunoglobulina enriquecida con anti-LPS para su uso en el tratamiento y/o la profilaxis de esteatohepatitis no alcohólica
JP2011026252A (ja) * 2009-07-27 2011-02-10 Kitasato Institute 上皮成長因子受容体に対する卵黄抗体およびその用途
AU2011290478B2 (en) 2010-08-17 2014-11-13 Hadasit Medical Research Services & Development Limited Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
PH12013501040A1 (en) 2010-11-23 2022-10-24 Pantheryx Inc Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
US20140302034A1 (en) * 2010-12-08 2014-10-09 Stem Centrx, Inc. Novel modulators and methods of use
WO2012098256A1 (en) * 2011-01-21 2012-07-26 Université De La Méditerranée Aix - Marseille Ii Anti-cd146 auto-antibodies and uses thereof
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
WO2013080050A2 (en) * 2011-11-30 2013-06-06 Universitaetsklinikum Erlangen Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
US10792320B2 (en) * 2018-03-28 2020-10-06 Michael Alan Beller Methods for treatment of bladder dysfunction
US12263192B2 (en) 2019-02-26 2025-04-01 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
US11319382B1 (en) 2021-06-28 2022-05-03 King Abdulaziz University Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303869A (zh) * 1999-10-22 2001-07-18 徐永华 鸡蛋黄抗白细胞介素－8抗体、制备方法及其应用
WO2003080082A1 (en) * 2002-03-21 2003-10-02 Anadis Ltd Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006083936A2 (en) * 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911108A (en) * 1973-02-14 1975-10-07 Diamond Shamrock Corp Process of producing bovine milk products containing specific antibodies
AUPN642795A0 (en) * 1995-11-08 1995-11-30 Northfield Laboratories Pty Ltd Dairy compositions and methods of preparing same
KR20000048855A (ko) * 1996-10-02 2000-07-25 오비뮨, 인크. 닭의 난황 항체를 경구 투여하여 질병을 치료하는 방법
CN1304312A (zh) * 1998-01-19 2001-07-18 Dcv公司 治疗和预防关节炎和/或自身免疫疾病的组合物与方法
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
CN1303889A (zh) 1999-12-20 2001-07-18 陶氏康宁东丽硅氧烷株式会社 用于嵌件模塑或双模腔模塑的硅橡胶组合物
JP2005298332A (ja) * 2000-09-28 2005-10-27 Shibayagi:Kk 過剰自己抗体産生抑制物質、その製造法およびその使用方法
CN1199672C (zh) 2002-04-17 2005-05-04 李永忠 一套预防与治疗癌症中成药
CN1377894A (zh) * 2002-04-23 2002-11-06 郭占军 蛋黄抗癌抗体制备方法及其应用
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
JP4264894B2 (ja) * 2004-03-01 2009-05-20 三菱自動車工業株式会社 エアボックス付きグローブボックス
CA2584804A1 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
CN101253198A (zh) 2005-08-29 2008-08-27 独立行政法人科学技术振兴机构 使用鸵鸟产生的抗体及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303869A (zh) * 1999-10-22 2001-07-18 徐永华 鸡蛋黄抗白细胞介素－8抗体、制备方法及其应用
WO2003080082A1 (en) * 2002-03-21 2003-10-02 Anadis Ltd Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006083936A2 (en) * 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same

Also Published As

Publication number Publication date
EP2061510B1 (en) 2016-06-22
US20100297140A1 (en) 2010-11-25
WO2008025099A1 (en) 2008-03-06
DK2061510T3 (en) 2016-09-05
NZ575918A (en) 2012-03-30
US8834872B2 (en) 2014-09-16
CN101626784A (zh) 2010-01-13
US20130295109A1 (en) 2013-11-07
EP2061510A1 (en) 2009-05-27
EP2061510A4 (en) 2011-01-05
AU2007291891B2 (en) 2013-10-31
AU2007291891A1 (en) 2008-03-06
JP2010501596A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
CN101626784B (zh) 利用包含抗体的组合物治疗和/或预防非传染性医学病症
TWI852695B (zh) 抗體-藥物結合物之用途
JP6359492B2 (ja) 抗ＩＬ−１α抗体による癌の処置方法
EP1360203B1 (en) Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions
BR112019025188A2 (pt) Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
US20120266264A1 (en) Monoclonal antibodies against gonadotropin-releasing hormone receptor
TW201815423A (zh) 免疫性／治療性聚醣組合物及其用途
BR112020011664A2 (pt) composição farmacêutica do anticorpo lag-3 e seu uso
JP2022512709A (ja) 炎症性疾患及び自己免疫疾患を処置する組成物及び方法
JP7158142B2 (ja) 低体温改善剤
AU2022291618B2 (en) Anti-HMMW antibody, composition comprising same, and nucleic acid molecule encoding same, and use thereof
JP2022046576A (ja) 炎症性障害の治療療法
CN103275226B (zh) 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
WO2021218895A1 (zh) 针对PD-1和TGF-β的双功能蛋白
CA3211334A1 (en) Multispecific binding agents against cd40 and cd137 in therapy
TWI862564B (zh) 癌治療用醫藥
CN120795151A (zh) 抗犬pd-l1单克隆抗体及其在制备抗癌药物方面的应用
CN121002061A (zh) 抗cith3抗体及其用途
BR112021015940A2 (pt) Anticorpo anti-bag2 e métodos de tratamento de câncer
WO2020256110A1 (ja) タイトジャンクション形成誘導剤
CN114225024A (zh) 一种用于治疗疾病的益生菌药物或保健品
JP2011026252A (ja) 上皮成長因子受容体に対する卵黄抗体およびその用途
JP2020535214A (ja) がんの予防および／または治療に利用するための抗プレセニリン抗体またはそのフラグメント

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130717

Termination date: 20210831

CF01 Termination of patent right due to non-payment of annual fee